<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1012471</article-id><article-id pub-id-type="publisher-id">ACM-39434</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201200000_82958108.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  年龄及PSA对检出前列腺癌的影响
  Effects of Age and PSA on the Positive Rate of Prostate Cancer Biopsy
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>亚如</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>佳强</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>白</surname><given-names>宝艳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>胜利</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>魏</surname><given-names>君慈</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学附属医院，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>12</month><year>2020</year></pub-date><volume>10</volume><issue>12</issue><fpage>3151</fpage><lpage>3158</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨年龄、前列腺特异性抗原(prostate specific antigen, PSA)不同组合时对前列腺癌(Prostate Cancer, PCa)检出的影响，分析年龄和PSA的相关性。方法：连续回顾性分析2016年7月至2019年9月于我院怀疑为前列腺癌并行超声引导下经直肠前列腺穿刺的患者，共83例。收集年龄、前列腺体积、PSA、穿刺针数和病理结果等相关资料。患者按照年龄分为&lt;70岁和≥70岁组，按照PSA分为&lt;20 ng/ml和≥20 ng/ml组。利用χ
   <sup>2</sup>检验判断年龄及PSA对提高前列腺癌检出有无影响，年龄和PSA相关性分析采用皮尔逊相关性分析。结果：年龄 &lt; 70岁组和≥70组前列腺癌阳性率有统计学差异(p &lt; 0.010)；PSA &lt; 20 ng/ml和≥20 ng/ml组前列腺癌阳性率有统计学差异p = 0.015 (p &lt; 0.05)；年龄 ≥ 70岁并且PSA ≥ 20 ng/ml组前列腺癌阳性率与年龄 &lt; 70岁并且PSA &lt; 20 ng/ml有统计学差异p = 0.001 (p &lt; 0.008)。年龄与PSA成正相关关系，相关系数为0.298，p = 0.006 (p &lt; 0.05)，前列腺癌患者和非前列腺癌患者年龄和PSA不存在相关性，p分别为0.213，0.653 (p &gt; 0.05)。结论：年龄 ≥ 70岁且PSA ≥ 20 ng/ml人群，有较高的前列腺癌阳性率，均应尽早活检，明确诊断，为尽早临床干预提供时机。对其他组人群，应用影像新技术提高前列腺癌阳性率。年龄 &lt; 70岁且PSA &lt; 20 ng/ml人群，应充分结合影像学、其他实验室检查、临床表现及患者意愿综合考虑是否行前列腺穿刺活检，以免进行不必要的穿刺活检。年龄与PSA成正相关，前列腺癌、非前列腺癌患者年龄与PSA无相关关系。
    Objective: To explore the effect of different combinations of age and PSA on the positive rate of prostate cancer biopsy, and to preliminary analyze the correlation between age and PSA. Methods: A continuous retrospective analysis of 83 patients from July 2016 to September 2019 in our hospital who were suspected of having prostate cancer and ultrasound-guided transrectal prostate puncture. Collect relevant data such as age, prostate volume, PSA, number of puncture needles and pathological results. Patients were divided into groups of &lt;70 years and ≥70 years according to age, and into groups of &lt;20 ng/ml and ≥20 ng/ml according to PSA. Use the 
   χ
   <sup>2</sup> test to determine whether age and PSA have an effect on increasing the positive rate of prostate cancer. Pearson’s correlation analysis was used to analyze the correlation between age and PSA. Results: There was a statistically significant difference in the positive rate of prostate cancer between the age group &lt;70 years and ≥70 group (p &lt; 0.010); PSA &lt; 20 ng/ml and ≥20 ng/ml group had a statistically significant difference in prostate cancer positive rate p = 0.015 (p &lt; 0.05); the positive rate of prostate cancer in the group ≥70 years old and PSA ≥ 20 ng/ml was statistically different from the age &lt;70 years old and PSA &lt; 20 ng/ml, p = 0.001 (p &lt; 0.008). Age was positively correlated with PSA, the correlation coefficient was 0.298, p = 0.006 (p &lt; 0.05), there was no correlation between age and PSA in patients with prostate cancer and non-prostate cancer, p was 0.213, 0.653 (p &gt; 0.05). Conclusion: People aged ≥ 70 years and PSA ≥ 20 ng/ml have a higher positive rate of prostate cancer. All should be biopsy as soon as possible to confirm the diagnosis and provide the opportunity for early clinical intervention. For other groups of people, the application of new imaging technology to improve the positive rate of prostate cancer. People aged &lt; 70 years and PSA &lt; 20 ng/ml should fully consider whether to perform prostate biopsy based on imaging, other laboratory tests, clinical manifestations and patient’s wishes, so as to avoid unnecessary biopsy. Age is positively correlated with PSA, and there is no correlation between age of patients with prostate cancer and non-prostate cancer and PSA. 
  
 
</p></abstract><kwd-group><kwd>前列腺癌，年龄，前列腺特异性抗原, Prostate Cancer</kwd><kwd> Age</kwd><kwd> PSA</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨年龄、前列腺特异性抗原(prostate specific antigen, PSA)不同组合时对前列腺癌(Prostate Cancer, PCa)检出的影响，分析年龄和PSA的相关性。方法：连续回顾性分析2016年7月至2019年9月于我院怀疑为前列腺癌并行超声引导下经直肠前列腺穿刺的患者，共83例。收集年龄、前列腺体积、PSA、穿刺针数和病理结果等相关资料。患者按照年龄分为&lt;70岁和≥70岁组，按照PSA分为&lt;20 ng/ml和≥20 ng/ml组。利用 χ 2 检验判断年龄及PSA对提高前列腺癌检出有无影响，年龄和PSA相关性分析采用皮尔逊相关性分析。结果：年龄 &lt; 70岁组和≥70组前列腺癌阳性率有统计学差异(p &lt; 0.010)；PSA &lt; 20 ng/ml和≥20 ng/ml组前列腺癌阳性率有统计学差异p = 0.015 (p &lt; 0.05)；年龄 ≥ 70岁并且PSA ≥ 20 ng/ml组前列腺癌阳性率与年龄 &lt; 70岁并且PSA &lt; 20 ng/ml有统计学差异p = 0.001 (p &lt; 0.008)。年龄与PSA成正相关关系，相关系数为0.298，p = 0.006 (p &lt; 0.05)，前列腺癌患者和非前列腺癌患者年龄和PSA不存在相关性，p分别为0.213，0.653 (p &gt; 0.05)。结论：年龄 ≥ 70岁且PSA ≥ 20 ng/ml人群，有较高的前列腺癌阳性率，均应尽早活检，明确诊断，为尽早临床干预提供时机。对其他组人群，应用影像新技术提高前列腺癌阳性率。年龄 &lt; 70岁且PSA &lt; 20 ng/ml人群，应充分结合影像学、其他实验室检查、临床表现及患者意愿综合考虑是否行前列腺穿刺活检，以免进行不必要的穿刺活检。年龄与PSA成正相关，前列腺癌、非前列腺癌患者年龄与PSA无相关关系。</p></sec><sec id="s2"><title>关键词</title><p>前列腺癌，年龄，前列腺特异性抗原</p></sec><sec id="s3"><title>Effects of Age and PSA on the Positive Rate of Prostate Cancer Biopsy</title><p>Yaru Li, Jiaqiang Wang, Baoyan Bai, Shengli Wang, Junci Wei</p><p>Affiliated Hospital of Yan’an University, Yan’an Shaanxi</p><p><img src="//html.hanspub.org/file/41-1571766x5_hanspub.png" /></p><p>Received: Nov. 21<sup>st</sup>, 2020; accepted: Dec. 21<sup>st</sup>, 2020; published: Dec. 28<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/41-1571766x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To explore the effect of different combinations of age and PSA on the positive rate of prostate cancer biopsy, and to preliminary analyze the correlation between age and PSA. Methods: A continuous retrospective analysis of 83 patients from July 2016 to September 2019 in our hospital who were suspected of having prostate cancer and ultrasound-guided transrectal prostate puncture. Collect relevant data such as age, prostate volume, PSA, number of puncture needles and pathological results. Patients were divided into groups of &lt;70 years and ≥70 years according to age, and into groups of &lt;20 ng/ml and ≥20 ng/ml according to PSA. Use the χ 2 test to determine whether age and PSA have an effect on increasing the positive rate of prostate cancer. Pearson’s correlation analysis was used to analyze the correlation between age and PSA. Results: There was a statistically significant difference in the positive rate of prostate cancer between the age group &lt;70 years and ≥70 group (p &lt; 0.010); PSA &lt; 20 ng/ml and ≥20 ng/ml group had a statistically significant difference in prostate cancer positive rate p = 0.015 (p &lt; 0.05); the positive rate of prostate cancer in the group ≥70 years old and PSA ≥ 20 ng/ml was statistically different from the age &lt;70 years old and PSA &lt; 20 ng/ml, p = 0.001 (p &lt; 0.008). Age was positively correlated with PSA, the correlation coefficient was 0.298, p = 0.006 (p &lt; 0.05), there was no correlation between age and PSA in patients with prostate cancer and non-prostate cancer, p was 0.213, 0.653 (p &gt; 0.05). Conclusion: People aged ≥ 70 years and PSA ≥ 20 ng/ml have a higher positive rate of prostate cancer. All should be biopsy as soon as possible to confirm the diagnosis and provide the opportunity for early clinical intervention. For other groups of people, the application of new imaging technology to improve the positive rate of prostate cancer. People aged &lt; 70 years and PSA &lt; 20 ng/ml should fully consider whether to perform prostate biopsy based on imaging, other laboratory tests, clinical manifestations and patient’s wishes, so as to avoid unnecessary biopsy. Age is positively correlated with PSA, and there is no correlation between age of patients with prostate cancer and non-prostate cancer and PSA.</p><p>Keywords:Prostate Cancer, Age, PSA</p><disp-formula id="hanspub.39434-formula40"><graphic xlink:href="//html.hanspub.org/file/41-1571766x8_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/41-1571766x9_hanspub.png" /> <img src="//html.hanspub.org/file/41-1571766x10_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>前列腺癌是105个国家和地区最常见的疾病，以澳大利亚、新西兰、欧洲和美国等国家为著，发病率和死亡率分别居全球男性恶性肿瘤第二位和第五位，是我国恶性肿瘤发病率第六位，并且年龄标准化死亡率呈上升趋势 [<xref ref-type="bibr" rid="hanspub.39434-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.39434-ref2">2</xref>]，是威胁男性健康的重要疾病。1960 [<xref ref-type="bibr" rid="hanspub.39434-ref3">3</xref>] 年前列腺特异性抗原被发现，至今广泛的应用于临床筛查。现认为PSA &gt; 4 ng/ml是异常的，但前列腺癌穿刺阳性率为35% [<xref ref-type="bibr" rid="hanspub.39434-ref4">4</xref>]。对于如何提高前列腺癌活检阳性率，超声新技术、磁共振成像 [<xref ref-type="bibr" rid="hanspub.39434-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.39434-ref6">6</xref>] 等手段均可提高前列腺癌活检阳性率。年龄是预测前列腺癌穿刺阳性率的重要危险因素之一，说明年龄与PSA对前列腺癌的检出有至关重要的作用，不同年龄与PSA的组合是否可以提高前列腺癌的检出是个值得探讨的问题。</p></sec><sec id="s6"><title>2. 材料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><p>连续收集2016年7月至2019年9月于我院怀疑为前列腺癌并行超声引导下经直肠前列腺穿刺的患者。</p><p>收集资料：记录患者年龄、前列腺体积、PSA、穿刺针数、病理结果。</p></sec><sec id="s6_2"><title>2.2. 纳入标准</title><p>1) 直肠指检可触及异常结节；2) MR、超声等检查有异常区域或结节；3) PSA检查前未经过治疗、前列腺按摩及既往无前列腺手术史，PSA &gt; 4 ng/ml [<xref ref-type="bibr" rid="hanspub.39434-ref4">4</xref>]；4) 受试者自愿参加，并签署知情同意书，该研究获得伦理委员会批准。</p></sec><sec id="s6_3"><title>2.3. 排除标准</title><p>1) 合并心肝肾等功能严重不全及其他系统恶性肿瘤者；2) 凝血功能障碍及免疫系统疾病；3) 临床资料不完整者；4) 严重内痔、肛裂及肛直肠手术患者。</p></sec><sec id="s6_4"><title>2.4. PSA检测方法</title><p>检查前无治疗史，未经尿道检查操作，未进行前列腺按摩操作，受试者均空腹抽取静脉血，采用电化学发光法检测，试剂盒由罗氏诊断产品(上海)有限公司提供。</p></sec><sec id="s6_5"><title>2.5. 仪器与方法</title><sec id="s6_5_1"><title>2.5.1. 体积计算方法</title><p>根据彩色超声和磁共振检查获得，体积V = 0.52 &#215; 左右经 &#215; 上下径 &#215; 前后径 [<xref ref-type="bibr" rid="hanspub.39434-ref7">7</xref>]，若两者均有体积参数，采取简单易得的超声测量数据记录。</p></sec><sec id="s6_5_2"><title>2.5.2. 经直肠超声引导前列腺穿刺检查</title><p>选用GE logic E9直肠腔内探头，所有患者检查前均行灌肠准备，行一般术前实验室检查。患者排空膀胱，取左侧卧位，充分暴露肛门，碘伏纱布消毒肛周及直肠2~3次，盐酸丁卡因胶浆表面麻醉，铺无菌洞巾，直肠腔内探头上固定穿刺架置入直肠，进行常规检查后行穿刺检查，穿刺枪为BARD自动活检枪，穿刺针为18G 25 cm一次性穿刺活检针。术后置入碘伏纱布消毒并压迫止血，应用抗生素，术后患者平卧硬板床6~12 h，密切关注患者有无出血、疼痛等症状，并积极处理。</p></sec></sec><sec id="s6_6"><title>2.6. 统计学分析</title><p>采用spss25.0统计学软件，将年龄和PSA进行分组，比较两组数据有无差异，计数资料比较行 χ 2 检验，若不满足 χ 2 检验的要求，进行Fisher精确检验，年龄和PSA相关性分析采用皮尔逊相关性分析，P值均为双尾，p &lt; 0.05表示差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 纳入患者一般临床资料</title><p>收集102例患者资料，排除资料不完整19例，共收集资料83例，平均年龄70.28 &#177; 7.35 (54~88)岁；中位PSA 20.90 (4.48~100) ng/ml，其中&gt;100 ng/ml 15例；83例患者中前列腺癌29例，非前列腺癌54例，穿刺阳性率34.94%，所有患者均无严重穿刺后并发症。如表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Clinical characteristics of included patients (n = 83</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >临床特点</th><th align="center" valign="middle" >纳入特征</th></tr></thead><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;70</td><td align="center" valign="middle" >37 (44.58%)</td></tr><tr><td align="center" valign="middle" >≥70</td><td align="center" valign="middle" >46 (55.42%)</td></tr><tr><td align="center" valign="middle" >中位PSA (ng/ml)</td><td align="center" valign="middle" >20.90 (4.48~100)</td></tr><tr><td align="center" valign="middle" >中位体积(ml)</td><td align="center" valign="middle" >54.0 (12.73~321.24)</td></tr><tr><td align="center" valign="middle" >&lt;50</td><td align="center" valign="middle" >39 (46.99%)</td></tr><tr><td align="center" valign="middle" >≥50</td><td align="center" valign="middle" >44 (53.01%)</td></tr><tr><td align="center" valign="middle" >平均穿刺针数</td><td align="center" valign="middle" >12 (6~16)</td></tr><tr><td align="center" valign="middle" >病理结果</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >前列腺癌</td><td align="center" valign="middle" >29 (34.94%)</td></tr><tr><td align="center" valign="middle" >非前列腺癌</td><td align="center" valign="middle" >54 (65.06%)</td></tr></tbody></table></table-wrap><p>表1. 纳入患者临床特点(n = 83)</p></sec><sec id="s7_2"><title>3.2. 年龄对前列腺癌阳性率的影响</title><p>根据年龄70岁将患者分为&lt;70岁组和≥70岁组，&lt;70岁组，前列腺癌占18.92%，非前列腺癌占81.02%；≥70岁组前列腺癌占45.65%，非前列腺癌占54.35%，两组年龄前列腺癌阳性率有差异，具有统计学意义p = 0.010 (p &lt; 0.05)。如表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Effect of age on the positive rate of prostate cance</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别(岁)</th><th align="center" valign="middle" >前列腺癌</th><th align="center" valign="middle" >非前列腺癌</th><th align="center" valign="middle" >总例数</th><th align="center" valign="middle" >阳性率(%)</th></tr></thead><tr><td align="center" valign="middle" >&lt;70</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >37</td><td align="center" valign="middle" >18.92</td></tr><tr><td align="center" valign="middle" >≥70</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >46</td><td align="center" valign="middle" >45.65</td></tr><tr><td align="center" valign="middle" >χ 2</td><td align="center" valign="middle" >6.556</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >p</td><td align="center" valign="middle" >0.010</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表2. 年龄对前列腺癌阳性率的影响</p></sec><sec id="s7_3"><title>3.3. PSA对前列腺癌阳性率的影响</title><p>将患者按照PSA 20 ng/ml分为&lt;20 ng/ml和≥20 ng/ml两组，&lt;20 ng/ml组内，前列腺癌8例，占21.5%，非前列腺癌30例，占78.95%；其中4~10 ng/ml 13例，前列腺癌3例，占23.08%，10~20 ng/ml 25例，前列腺癌5例，占20%；≥20 ng/ml组，前列腺癌发生21例，占46.67%，非前列腺癌24例，占53.33%，两组PSA前列腺癌阳性率有统计学差异p = 0.015 (p &lt; 0.05)。见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Effect of PSA on the positive rate of prostate cance</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >前列腺癌数</th><th align="center" valign="middle" >非前列腺癌</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >阳性率(%)</th></tr></thead><tr><td align="center" valign="middle" >&lt;20</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" >21.05</td></tr><tr><td align="center" valign="middle" >≥20</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >45</td><td align="center" valign="middle" >46.67</td></tr><tr><td align="center" valign="middle" >χ 2</td><td align="center" valign="middle" >5.946</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >p</td><td align="center" valign="middle" >0.015</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表3. PSA对前列腺癌阳性率的影响</p></sec><sec id="s7_4"><title>3.4. 年龄和PSA相关性分析</title><p>对年龄和PSA进行双变量相关性分析，显示年龄与PSA成正相关关系，相关系数为0.298，P = 0.006 (P &lt; 0.05)。按照病理结果将患者分为前列腺癌和非前列腺癌组，前列腺癌患者和非前列腺癌患者年龄和PSA不存在相关性，r分别为0.238、0.063，p分别为0.213、0.653 (p &gt; 0.05)，如下图1。</p><p>图1. 年龄和PSA相关性分析</p></sec><sec id="s7_5"><title>3.5. 不同年龄、PSA组合对前列腺癌阳性率的影响</title><p>按照年龄和PSA不同组合计算出 χ 2 为24.154，p = 0.001 (&lt;0.05)，8组阳性率有差异。对α进行校正，得α = 0.0018，分别进行两两率 χ 2 检验，其中第5组和第8组， χ 2 = 11.016，P = 0.001 (&lt;0.008)，认为年龄 &lt; 70岁并且PSA &lt; 20 ng/ml与年龄 ≥ 70岁并且PSA ≥ 20 ng/ml对检出前列腺癌阳性率有统计学差异。如表4。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Effect of different combinations on the positive rate of prostate cancer biops</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别(岁，ng/ml)</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >前列腺癌数</th><th align="center" valign="middle" >非前列腺癌</th><th align="center" valign="middle" >阳性率(%)</th></tr></thead><tr><td align="center" valign="middle" >&lt;70(1)</td><td align="center" valign="middle" >37</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >18.92</td></tr><tr><td align="center" valign="middle" >≥70(2)</td><td align="center" valign="middle" >46</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >54.35</td></tr><tr><td align="center" valign="middle" >&lt;20(3)</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >21.05</td></tr><tr><td align="center" valign="middle" >≥20(4)</td><td align="center" valign="middle" >45</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >46.67</td></tr><tr><td align="center" valign="middle" >&lt;70，&lt;20(5)</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >9.5</td></tr><tr><td align="center" valign="middle" >&lt;70，≥20(6)</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >31.25</td></tr><tr><td align="center" valign="middle" >&gt;70，＜20(7)</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >29.41</td></tr><tr><td align="center" valign="middle" >&gt;70，≥20(8)</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >55.17</td></tr><tr><td align="center" valign="middle" >χ 2</td><td align="center" valign="middle" >24.154</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >p</td><td align="center" valign="middle" >0.001</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表4. 不同组合对前列腺癌活检阳性率的影响</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>Hodges教授 [<xref ref-type="bibr" rid="hanspub.39434-ref8">8</xref>] 首次报道超声引导下经直肠前列腺6针穿刺方法，为临床提供了一种前列腺癌的高精度诊断方法，并广泛的应用于临床，是术前诊断的金标准。目前筛查前列腺癌的PSA截断值为4 ng/ml，明显提高了前列腺癌的检出，随之穿刺活检率也大大增高了，前列腺穿刺术是一项侵入性操作，在提高前列腺癌检出的同时，也带来出血、感染、疼痛等穿刺并发症，导致穿刺活检后泌尿外科并发症的住院率增加 [<xref ref-type="bibr" rid="hanspub.39434-ref9">9</xref>]。</p><p>前列腺癌穿刺阳性率为34.94%，与Vickers [<xref ref-type="bibr" rid="hanspub.39434-ref4">4</xref>] 等人的结论相近。在PSA异常的患者中仍有65.06%活检结果为非前列腺癌病变。PSA是由前列腺腺细胞合成的糖蛋白，正常生理情况下，主要局限在前列腺组织中，当正常组织遭受挤压、侵犯时，前列腺特异性抗原入血，导致浓度上升，故在良性前列腺增生、急性前列腺炎、尿滁留等疾病中可升高 [<xref ref-type="bibr" rid="hanspub.39434-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.39434-ref11">11</xref>]。也有学者指出前列腺特异性抗原并非具有前列腺特异性，在女性乳汁中也可检出中也可检出前列腺特异性抗原 [<xref ref-type="bibr" rid="hanspub.39434-ref12">12</xref>]，因此对前列腺疾病的良恶性判断有较低的特异度。美国自从在50岁以上男性中开始筛查PSA，PCa的发病率和死亡率有所下降，在2001年~2017年期间，死亡率为19.1% [<xref ref-type="bibr" rid="hanspub.39434-ref13">13</xref>]，且发现时多处于早期。我国目前多对有尿道症状的患者进行PSA筛查，并没有进行广泛健康人群PSA筛查，是因为我国的发病率明显低于欧美国家 [<xref ref-type="bibr" rid="hanspub.39434-ref14">14</xref>]，进行PSA筛查的利弊需要更多研究来支持。</p><p>研究指出，前列腺癌是中老年男性较常见的疾病之一，以70岁为界限70岁之前缓慢上升趋势，70岁后发病率呈快速上升趋势 [<xref ref-type="bibr" rid="hanspub.39434-ref15">15</xref>]。入组患者年龄在54~88岁之间，故采用70岁为分组依据，分为两组。≥70岁组穿刺为前列腺癌的患者数明显高于&lt;70岁组，与前列腺癌的发病趋势保持一致。若单用年龄进行穿刺结果，会存在很大程度上的漏诊，应联合PSA或其他指标综合判断。</p><p>徐建峰 [<xref ref-type="bibr" rid="hanspub.39434-ref14">14</xref>] 研究发现，我国男性PSA的灰色区域不是4~9.9 ng/ml，而是10~19.9 ng/ml。陈瑞 [<xref ref-type="bibr" rid="hanspub.39434-ref16">16</xref>] 等人指出PSA在4~10 ng/ml范围内PCa的阳性率为25.1%；Kandıralı [<xref ref-type="bibr" rid="hanspub.39434-ref17">17</xref>] 指出PSA在10~20 ng/ml范围内穿刺阳性率为25%。唐萍 [<xref ref-type="bibr" rid="hanspub.39434-ref18">18</xref>] 认为PSA在4~10 ng/ml与10~20 ng/ml范围内阳性率没有差异，分别为20.5%，21.6%，Chavan [<xref ref-type="bibr" rid="hanspub.39434-ref19">19</xref>] 等人前列腺癌穿刺阳性率虽然较唐萍等人的研究低，但结论相似，认为PSA 4~10 ng/ml与10~20 ng/ml时穿刺活检阳性率较低，故将PSA按照20 ng/ml分为两组。</p><p>PSA在&lt;20 ng/ml范围内，前列腺癌阳性率为21.05%，与唐萍 [<xref ref-type="bibr" rid="hanspub.39434-ref18">18</xref>] 等人研究结果相近。PSA在≥20 ng/ml范围内，阳性率从53%~95% [<xref ref-type="bibr" rid="hanspub.39434-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.39434-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.39434-ref21">21</xref>] 不等，稍高于46.67%，由于该研究病例数较少，存在抽样误差，但较21.05%明显增高，认为PSA以20 ng/ml为界限分组时穿刺阳性率存在差异，当PSA ≥ 20 ng/ml可以明显提高穿刺阳性率。</p><p>PSA随着年龄增长而增长，成正相关关系，我国北京、西安、大连地区 [<xref ref-type="bibr" rid="hanspub.39434-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.39434-ref23">23</xref>] [<xref ref-type="bibr" rid="hanspub.39434-ref24">24</xref>] 的研究结果均证实了这一点，进而说明不同年龄段应设置不同的PSA值。对于前列腺癌患者来说，其年龄与PSA没有明显的线性相关关系，与国内王功伟 [<xref ref-type="bibr" rid="hanspub.39434-ref25">25</xref>] 等人报告的前列腺癌患者的年龄和PSA呈曲线相关关系不同，可能由于纳入的年龄范围不同，结果中患者年龄在(54~88)岁之间，而王功伟等人研究年龄在(38~96)岁之间，并且排除了游离前列腺特异性抗原 &gt; 50 ng/ml的患者，从而造成研究结果上的差异。赵佳 [<xref ref-type="bibr" rid="hanspub.39434-ref26">26</xref>] 等人与本文研究结果相似，认为前列腺癌患者PSA水平与年龄无相关性。无相关性的原因可能为前列腺癌患者PSA水平主要与肿瘤细胞破坏能力有关。非前列腺癌患者主要病理类型为良性前列腺增生，PSA水平与年龄也呈无明显相关关系，其影响因素主要与前列腺体积有关 [<xref ref-type="bibr" rid="hanspub.39434-ref27">27</xref>]。</p><p>当年龄 ≥ 70岁并且PSA ≥ 20 ng/ml时，前列腺癌阳性率最高，明显较&lt;70岁并且PSA &lt; 20岁阳性率高。2013年荣娜 [<xref ref-type="bibr" rid="hanspub.39434-ref28">28</xref>] 等人认为根据不同年龄分组制定不同的PSA截断值，tPSA临界值分别为19.0 ng/mL (年龄 ≤ 60)，21.0 ng/mL (61~80岁)，≥81岁男性的PSA值为23.0 ng/mL。其研究结果截断值均大于4 ng/ml，说明对于我国人群，不同年龄组、不同PSA应该按照不同的截断值来指导穿刺检查。</p><p>综上所述，我国对于年龄 ≥ 70岁且PSA ≥ 20 ng/ml人群，有较高的前列腺癌阳性率，应尽早穿刺，明确诊断，为尽早临床干预提供时机；对于年龄 &lt; 70岁且PSA &lt; 20 ng/ml人群，应充分结合影像学、其他实验室检查、临床表现及患者意愿综合考虑是否行前列腺穿刺活检，以免进行不必要的穿刺活检；对其他组人群，应结合其他检查方法提高前列腺癌穿刺阳性率。</p></sec><sec id="s9"><title>文章引用</title><p>李亚如,王佳强,白宝艳,王胜利,魏君慈. 年龄及PSA对检出前列腺癌的影响Effects of Age and PSA on the Positive Rate of Prostate Cancer Biopsy[J]. 临床医学进展, 2020, 10(12): 3151-3158. https://doi.org/10.12677/ACM.2020.1012471</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.39434-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Cai, Z. and Liu, Q. (2019) Understanding the Global Cancer Statistics 2018: Implications for Cancer Control. Science China Life Sciences. https://doi.org/10.1007/s11427-019-9816-1</mixed-citation></ref><ref id="hanspub.39434-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Chen, W., Zheng, R., Baade, P.D., et al. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132. https://doi.org/10.3322/caac.21338</mixed-citation></ref><ref id="hanspub.39434-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Flocks, R.H., Urich, V.C., Patel, C.A., et al. (1960) Studies on the Antigenic Properties of Prostatic Tissue. International Journal of Urology, 84, 134-143. https://doi.org/10.1016/S0022-5347(17)65503-4</mixed-citation></ref><ref id="hanspub.39434-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Vickers, A.J., Cronin, A.M., Roobol, M.J., et al. (2010) The Relationship between Prostate-Specific Antigen and Prostate Cancer Risk: The Prostate Biopsy Collaborative Group. Clinical Cancer Research, 16, 4374-4381.  
https://doi.org/10.1158/1078-0432.CCR-10-1328</mixed-citation></ref><ref id="hanspub.39434-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Kim, S.H., Choi, M.S., Kim, M.J., et al. (2017) Validation of Prostate Imaging Reporting and Data System Version 2 Using an MRI-Ultrasound Fusion Biopsy in Prostate Cancer Diagnosis. American Journal of Roentgenology, 209, 800-805. https://doi.org/10.2214/AJR.16.17629</mixed-citation></ref><ref id="hanspub.39434-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Barr, R.G., Cosgrove, D., Brock, M., et al. (2017) WFUMB Guidelines and Recommendations on the Clinical Use of Ultrasound Elastography: Part 5. Prostate. Ultrasound in Medicine and Biology, 43, 27-48.  
https://doi.org/10.1016/j.ultrasmedbio.2016.06.020</mixed-citation></ref><ref id="hanspub.39434-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">张帆, 黄毅, 陆敏, 马潞林. 临床低危型前列腺癌根治性切除术后病理升级的危险因素分析[J]. 微创泌尿外科杂志, 2013, 2(4): 280-283.</mixed-citation></ref><ref id="hanspub.39434-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Hodge, K.K., McNeal, J.E., Terris, M.K., et al. (1989) Random Systematic versus Directed Ultrasound-Guided Transrectal Core Biopsies of the Prostate. Journal d’Urologie, 142, 71-74. https://doi.org/10.1016/S0022-5347(17)38664-0</mixed-citation></ref><ref id="hanspub.39434-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Gaylis, F., Nasseri, R., Fink, L., et al. (2016) Prostate Biopsy Complications: A Dual Analysis. Urology, 93, 135-140.  
https://doi.org/10.1016/j.urology.2016.03.035</mixed-citation></ref><ref id="hanspub.39434-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">王炜, 李传刚, 刘辉, 等. 前列腺特异性抗原对前列腺癌诊断价值的探讨[J]. 中国医科大学学报, 2016, 45(1): 61-65+69.</mixed-citation></ref><ref id="hanspub.39434-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">魏强, 韩平. 前列腺特异性抗原与前列腺癌[J]. 临床外科杂志, 2006(2): 81-83.</mixed-citation></ref><ref id="hanspub.39434-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Mannello, F. and Gazzanelli, G. (2001) Prostate-Specific Antigen (PSA/hK3): A Further Player in the Field of Breast Cancer Diagnostics? Breast Cancer Research, 3, 238-243. https://doi.org/10.1186/bcr302</mixed-citation></ref><ref id="hanspub.39434-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Henley, S.J., Ward, E.M., Scott, S., et al. (2020) Annual Report to the Nation on the Status of Cancer, Part I: National Cancer Statistics. Cancer, 126, 2225-2249. https://doi.org/10.1002/cncr.32802</mixed-citation></ref><ref id="hanspub.39434-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Xu, J. (2014) The Xu’s Chart for Prostate Biopsy: A Visual Presentation of the Added Value of Biomarkers to Prostate-Specific Antigen for Estimating Detection Rates of Prostate Cancer. Asian Journal of Andrology, 16, 536-540.  
https://doi.org/10.4103/1008-682X.125907</mixed-citation></ref><ref id="hanspub.39434-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">韩苏军, 张思维, 陈万青, 等. 中国前列腺癌发病现状和流行趋势分析[J]. 鳞状肿瘤学杂志, 2013, 19(4): 330-334.</mixed-citation></ref><ref id="hanspub.39434-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Chen, R., Xie, L., Cai, X., et al. (2015) Percent Free Prostate-Specific Antigen for Prostate Cancer Diagnosis in Chinese Men with a PSA of 4.0-10.0 ng/mL: Results from the Chinese Prostate Cancer Consortium. Asian Journal of Urology, 2, 107-113. https://doi.org/10.1016/j.ajur.2015.04.022</mixed-citation></ref><ref id="hanspub.39434-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Kandıralı, E., Temiz, M.Z., Çolakerol, A., et al. (2018) Does the Prostate Volume Always Effect Cancer Detection Rate in Prostate Biopsy? Additional Role of Prostate-Specific Antigen Levels: A Retrospective Analysis of 2079 Patients. Turkish Journal of Urology, 45, 103-107. https://doi.org/10.5152/tud.2018.66909</mixed-citation></ref><ref id="hanspub.39434-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Tang, P., Du, W., Xie, K., et al. (2013) Transition Zone PSA Density Improves the Prostate Cancer Detection Rate Both in PSA 4.0-10.0 and 10.1-20.0 ng/ml in Chinese Men. Urologic Oncology, 31, 744-748.  
https://doi.org/10.1016/j.urolonc.2011.06.012</mixed-citation></ref><ref id="hanspub.39434-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Chavan, P.R., Chavan, S.V., Chavan, N.R., et al. (2009) Detection Rate of Prostate Cancer Using Prostate Specific Antigen in Patients Presenting with Lower Urinary Tract Symptoms: A Retrospective Study. Journal of Postgraduate Medicine, 55, 17-21. https://doi.org/10.4103/0022-3859.43548</mixed-citation></ref><ref id="hanspub.39434-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Yücel, C., Budak, S., Kısa, E., et al. (2018) The Sufficiency of 6 Core Sextant Prostate Biopsy in Patients with Prostate Specific Antigen (PSA) Values over 20 ng/ml. Archivio Italiano di Urologia e Andrologia, 90, 104-106.  
https://doi.org/10.4081/aiua.2018.2.104</mixed-citation></ref><ref id="hanspub.39434-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Kash, D.P., Lal, M., Hashmi, A.H., et al. (2014) Utility of Digital Rectal Examination, Serum Prostate Specific Antigen, and Transrectal Ultrasound in the Detection of Prostate Cancer: A Developing Country Perspective. Asian Pacific Journal of Cancer Prevention, 15, 3087-3091. https://doi.org/10.7314/APJCP.2014.15.7.3087</mixed-citation></ref><ref id="hanspub.39434-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">李昕, 张祥华, 张争, 等. 北京多中心社区50岁以上男性年龄与前列腺特异性抗原的关系[J]. 北京大学学报: 医学版, 2012, 44(2): 288-290.</mixed-citation></ref><ref id="hanspub.39434-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">王明珠, 高中伟, 贺大林, 等. 西安地区汉族成年健康男性年龄与血清前列腺特异性抗原的关系[J]. 中华医学杂志, 2003, 83(19): 1665-1667.</mixed-citation></ref><ref id="hanspub.39434-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">蔡凯, 刘志宇, 王梁, 等. 大连地区男性年龄相关前列腺特异性抗原参考值范围[J]. 中国医科大学学报, 2017, 46(10): 927-930.</mixed-citation></ref><ref id="hanspub.39434-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">王功伟, 沈丹华. 前列腺腺癌患者年龄与血清PSA相关性初步分析[J]. 现代泌尿生殖肿瘤杂志, 2014(3): 146-149.</mixed-citation></ref><ref id="hanspub.39434-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">赵佳, 王建华, 韩雪, 等. 前列腺癌患者特异性抗原的影响因素分析[J]. 健康教育与健康促进, 2015(6): 417-418.</mixed-citation></ref><ref id="hanspub.39434-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">李培军, 张祥华, 郭利君, 等. 血清PSA与良性前列腺增生临床病理的相关性研究[J]. 中华泌尿外科杂志, 2006, 27(6): 421-423.</mixed-citation></ref><ref id="hanspub.39434-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Na, R., Wu, Y., Xu, J., et al. (2013) Age-Specific Prostate Specific Antigen Cutoffs for Guiding Biopsy Decision in Chinese Population. PLoS ONE, 8, e67585. https://doi.org/10.1371/journal.pone.0067585</mixed-citation></ref></ref-list></back></article>